Search Bar & Filters
Found 234 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the effectiveness of delgocitinib cream 20 mgg applied twice daily compared to a non-active cream vehicle in treating adults with mild to severe palmoplantar pustulosis PPP, a condition characterized by pustules on the palms and soles. This phase 2a, double-blind study aims to provide proof-of-concept evidence over a 16-week treatment period. Participants will be randomly assigned to one of two groups one group will apply delgocitinib cream twice daily, and the other will apply a matching vehicle cream twice daily for 16 weeks. The study includes approximately 9 visits over about 18 weeks in total, covering treatment and follow-up periods. Throughout the trial, participants will attend scheduled visits for assessments including skin evaluations, photography confirmation of PPP, and various symptom and quality of life measures. Researchers will monitor improvements using the PPP Area and Severity Index PPPASI and Physician Global Assessment PGA, as well as track adverse events and changes in symptoms like itch and pain. The main outcome is the number of participants achieving at least a 75% improvement in PPPASI score after 16 weeks of treatment.
Actively Recruiting
Researchers are evaluating the use of delgocitinib cream applied twice daily to treat adults with mild to severe lichen sclerosus LS, focusing mainly on female participants since LS is more common in females. This Phase 3 trial is designed to assess the efficacy and safety of delgocitinib in comparison to a cream vehicle over a long period. The study includes two parts Part 1 enrolls females to determine the best dose, and Part 2 enrolls both males and females to further evaluate safety and efficacy. Participants will be assigned randomly to receive either delgocitinib cream at specified doses or a cream vehicle. Treatments are applied twice daily during an initial 12-week period followed by a continuation treatment period lasting 40 weeks. Various dosing regimens are used across groups, including delgocitinib cream alone, cream vehicle alone, or combinations transitioning between the two during the study. Male participants will be included in a substudy to evaluate delgocitinibs effects in men. During the trial, participants will attend clinic visits and undergo assessments including measurement of skin condition severity using the IGA-LS score, clinical lichen sclerosus score CLISSCO, and patient-reported scales for skin pain and itch. Quality of life related to vulvar symptoms will also be monitored. Safety is carefully tracked through adverse event reporting and laboratory tests throughout the study, which lasts from 55 to 60 weeks per participant. The primary outcome is the number of participants achieving a specific improvement in LS severity at week 12.
Actively Recruiting
Burn injuries can cause long-lasting physical and mental effects due to scarring and painful dressings. The usual treatment involves antibiotic topical dressings while waiting to determine the depth of the burn, followed by surgery for deeper burns. Assessing burn depth is difficult, and surgical removal of damaged tissue may remove some healthy tissue. New methods like hydro-dissection devices and enzymatic treatments like Bromolein have been explored but lack clear proof of benefit and may sometimes cause harm. This research compares PluroGel, a special gel that helps soften and remove dead tissue while keeping the wound moist, to the standard antibiotic ointment and gauze dressings. PluroGel is applied in a 0.5 cm layer with moist gauze twice daily, alongside the standard dressing applied three times a week. The study will assess if PluroGel improves wound healing and reduces the need for surgery. Participants will receive either the standard dressing or PluroGel treatment and will be followed for up to 14 days. Researchers will monitor wound healing, pain levels, satisfaction of patients and caregivers, and whether surgery is needed. The study uses a randomized, double-blind design and aims to provide evidence on the effectiveness of PluroGel in burn care.
Actively Recruiting
Researchers are investigating new treatment options for people with locally advanced or metastatic colorectal cancer mCRC that cannot be removed by surgery and has a specific gene mutation called KRAS G12C. The study aims to evaluate the safety and tolerance of combining calderasib, cetuximab, and mFOLFOX6 chemotherapy compared to the standard treatment of mFOLFOX6 with or without bevacizumab. This research is a phase 3 clinical trial focused on improving outcomes for this specific patient group. Participants will be assigned to one of two groups. One group receives calderasib tablets orally, cetuximab every two weeks, and mFOLFOX6 chemotherapy including oxaliplatin, leucovorin or levofolinate calcium, and 5-fluorouracil every two weeks. The other group receives mFOLFOX6 chemotherapy with or without bevacizumab or a bevacizumab biosimilar, also administered every two weeks. Treatment continues until doctors decide to stop based on specific criteria. During the study, participants will be closely monitored for side effects and treatment tolerability, with evaluations lasting up to about 44 months in the first part and up to 5 years in the second part. Researchers will collect data on progression-free survival, response rates, overall survival, and quality of life using various questionnaires. Safety assessments and tracking of any adverse events will be conducted regularly throughout the study.
Actively Recruiting
Researchers are evaluating the use of a high protein egg white pudding as a nutritional supplement for people with kidney failure who are on dialysis. The study aims to find out if giving this egg white pudding after dialysis is practical and whether it can improve blood protein levels, frailty, dietary intake, and other blood markers compared to a standard supplement called Ensure Plus. This trial is conducted by Seven Oaks Hospital Chronic Disease Innovation Centre. Participants will be randomly assigned to receive either the egg white protein pudding or Ensure Plus at the end of their dialysis treatments three times a week for 12 weeks. Both supplements are dietary and taken during the dialysis sessions. The study collects data during this 12-week intervention period to evaluate the effects of the two supplements. During the study, participants will be monitored for their ability to stay in the trial, adherence to the supplements, and health measures such as hand grip strength, walking speed, balance, and blood levels including serum albumin and electrolytes. These assessments occur at the end of the 12 weeks. The trial also tracks recruitment and follow-up rates to evaluate feasibility. Overall, participants are involved in regular supplement intake and health testing during dialysis over three months.
Actively Recruiting
Researchers are evaluating whether the drugs retatrutide and tirzepatide can prevent major adverse liver outcomes MALO in adults with metabolic dysfunction-associated steatotic liver disease MASLD, a condition that puts them at higher risk for severe liver problems. This Phase 3 trial is designed as a randomized, controlled study involving about 4,500 adults with MASLD identified through non-invasive tests indicating increased risk for liver complications. Participants will be randomly assigned to receive either retatrutide, tirzepatide, or a placebo, all given by subcutaneous injection. The study will last approximately 224 weeks, with up to 25 to 30 clinic visits to monitor health, conduct procedures, and assess liver function and disease progression. After completing the main study, eligible participants may join an optional 2-year extension where all receive either retatrutide or tirzepatide, regardless of initial assignment. Throughout the trial, participants will undergo assessments including liver fat content measurements, liver stiffness tests, liver fibrosis scores, and blood tests for liver enzymes and body weight changes. The primary outcome is the time until the first major adverse liver event occurs. Safety and disease progression will be closely monitored during and after treatment through regular clinic visits and evaluations.
Actively Recruiting
Researchers are studying the best steroid dose to treat acute T cell mediated rejection TCMR in people who have had kidney or kidney-pancreas transplants. TCMR is a type of rejection where the bodys immune system attacks the transplanted organ, which can cause serious complications or organ failure. This international, multi-center trial aims to find the lowest effective and safe steroid dose to manage this condition, addressing a long-standing question in transplant care. The trial compares four treatment approaches that differ in doses of intravenous methylprednisolone IV MP and oral prednisone taper. Participants receive either a high or low dose of IV MP for three days followed by a high or low dose of oral prednisone for seven days, then return to standard prednisone. This factorial design allows evaluation of both drugs dose effects. The study is sponsored by the University of Sydney and involves collaboration among several international transplant societies. Participants will be closely monitored with biopsies and blood tests to assess rejection resolution and kidney function over 12 weeks. Researchers will also track survival, kidney filtration rates, urine protein levels, infection rates, quality of life, and other health outcomes up to 48 weeks. The study includes regular visits and evaluations to ensure safety and collect data on treatment effects and side effects during the trial period.
Actively Recruiting
Healthy Volunteer
Cardiovascular disorders such as hypertension, heart attack, and stroke remain leading causes of illness and death globally. Unhealthy diets and inactive lifestyles are key modifiable risks for these conditions. Researchers are studying the effects of wild rice, a functional food with possible health benefits, on cardiovascular risk factors in healthy adults aged 20 to 40 over a 4-week period. This pilot study aims to explore wild rices impact and underlying mechanisms to support future larger trials. Participants will consume one serving daily of specially prepared foods containing about 30 grams of wild rice, including fruitvegetable salad, energy cookies, and casserole, for 28 days. These test foods are provided by Tall Grass Bakery. The study focuses on how regular wild rice intake may influence cardiovascular health by assessing changes in blood lipids, inflammatory markers, and gut bacteria. Throughout the study, researchers will collect blood and urine samples and perform vascular measurements at the start day 0 and end day 28. They will analyze serum lipids, inflammation markers, and types and amounts of fecal bacteria. The primary outcomes include changes in the gut microbiome and related macronutrient metabolism. Secondary outcomes examine improvements in blood lipid profiles and endothelial cell function. Participation lasts 4 weeks with close monitoring to assess these health indicators.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of intravenously administered YN001 in adults diagnosed with coronary atherosclerosis who are also receiving treatment for cardiovascular risk factors. This multinational, multicenter, randomized, double-blind, placebo-controlled Phase 2b clinical trial aims to compare different doses of YN001 with placebo in this population. Participants will be randomly assigned to receive one of three weekly intravenous treatments YN001 at 40mg, YN001 at 20mg, or a placebo at 0mg. Treatment will be administered once weekly for 13 weeks, totaling 13 doses. The study includes a screeningbaseline period lasting up to 12 weeks, a 12-week blinded treatment phase, followed by a 30-day safety follow-up and a long-term monitoring period lasting approximately 2 years after randomization. During the study, participants will undergo various assessments including imaging scans to measure changes in coronary and carotid artery plaque, blood tests to analyze YN001 concentration and immune responses, and monitoring for major adverse cardiac events. The primary measurement is the relative change in coronary non-calcified plaque volume from baseline to week 13. Safety and immune response will be closely tracked throughout treatment and follow-up, with total participation lasting up to about 2 years.
Actively Recruiting
Researchers are evaluating the safety and efficacy of GIA632 in adults aged 18 to 99 years with non-segmental vitiligo NSV. This randomized, double-blind, placebo-controlled Phase 2b study aims to identify the optimal dose of GIA632 to be further studied in a Phase 3 program. The study also includes an extension period to assess longer-term safety and effectiveness. Participants will be randomly assigned to one of several groups receiving either GIA632 or a placebo during a 48-week core treatment period. The study will measure the dose-response relationship of GIA632 and compare its effects with placebo. The extension phase will further evaluate the safety and efficacy over a longer term. During the study, participants will have regular assessments including measurement of facial and total body vitiligo area using the Vitiligo Area Scoring Index VASI at baseline and multiple time points up to 48 weeks. Researchers will also track improvements using the Vitiligo Noticeability Scale. Safety and treatment response will be monitored throughout the study period, which lasts up to approximately four years including follow-up.
1-10 of 234
1